Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;37(6):1201-1214.
doi: 10.1016/j.hoc.2023.05.011. Epub 2023 Jun 15.

The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies

Karthik Nath  1 , Sham Mailankody  2 , Saad Z Usmani  3
Affiliations
Review

The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies

Karthik Nath et al. Hematol Oncol Clin North Am. 2023 Dec.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are a class of T-cell engaging immunotherapies that have demonstrated considerable promise for patients with blood cancers. In comparison with traditional cancer therapeutics, T-cell engaging therapies harness the power of the host immune system to attack malignant cells expressing a target antigen of interest. Although these therapies are altering the natural history of blood cancers, the availability of several products has created uncertainty regarding treatment selection. In this review, we discuss the role of CAR T-cell therapy in the emerging era of bispecific antibodies with a particular focus on multiple myeloma.

Keywords: Bispecific antibodies; CAR T-cell therapy; Immunotherapeutic agents; Multiple myeloma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic of CAR T-cell and bispecific antibody therapy in MM
See this image and copyright information in PMC

References

    1. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine. 2021/February/25 2021;384(8):705–716. doi: 10.1056/NEJMoa2024850 - DOI - PubMed
    1. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet. 2021;398(10297):314–324. doi: 10.1016/S0140-6736(21)00933-8 - DOI - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. Dec 28 2017;377(26):2531–2544. doi: 10.1056/NEJMoa1707447 - DOI - PMC - PubMed
    1. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 2018;380(1):45–56. doi: 10.1056/NEJMoa1804980 - DOI - PubMed
    1. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. 2020;396(10254):839–852. doi: 10.1016/S0140-6736(20)31366-0 - DOI - PubMed

Publication types

MeSH terms

Substances